Psychedelics have a unique capacity to open up the mind so that everything feels fresh and full of possibilities. Especially as you get older, it can be easy to get stuck in a rut — but under a psychedelic, the brain can become more plastic. This time period, though, is limited - it might last just a few days, or a few weeks. So it’s really important to understand this “critical period” when our minds are so open — and also so vulnerable. These “critical periods” are what Gul Dolen has been studying for years. She’s a neuroscientist at Johns Hopkins that has done some groundbreaking investigation of the “critical periods” of psychedelics, including studies that involve giving MDMA — also known as “Molly” in some circles — to octopuses. She’s also challenging a lot of the scientific work that’s been done on psychedelics — she has serious doubts about the value of neuroimaging, or even a concept like the “default mode network.” If you heard our last Luminous episode on the neuroscience of psychedelics, you’ll want to listen to this interview. For more from Luminous, visit our website at ttbook.org/luminous Original Air Date: August 12, 2023 Interviews In This Hour: Guests: Gul Dolen Never want to miss an episode? Subscribe to the podcast. Want to hear more from us, including extended interviews and favorites from the archive? Subscribe to our newsletter.

Neuroscientists discuss the transformative effects of psychedelics on the brain, from exploring consciousness on toad venom to therapeutic potential for treating depression. Pioneers like Amanda Feilding and Robin Carhart-Harris delve into the entropic brain theory and the neuroscience of psychedelics, including serotonin 2A receptors.

Just a few years ago, it was pretty unusual to hear big-time celebrities talk about their own psychedelic experiences. But that stigma is starting to fade thanks to people like the rock star and music icon Melissa Etheridge.  For her, this psychedelic renaissance has gotten very personal. Three years ago, her son Beckett died at the age of 21 from an opioid drug overdose. When Etheridge heard that clinical trials with psilocybin were showing real promise for treating addiction, she became an outspoken advocate for psychedelic therapy. And she started her own nonprofit organization, the Etheridge Foundation, to support scientific research into the causes and treatments for opioid addiction.  Melissa Etheridge recently came through Madison, Wisconsin for an evening concert. Earlier that day, she stopped by the Usona Institute — which is running its own clinical trials on psilocybin and 5-MeO-DMT — where she sat down with Steve for a short interview. She talked about the death of her son, and her own life-changing experiences with ayahuasca. She explains why she’s fascinated by psychedelics as both a path for spiritual exploration and a source of creativity. Original Air Date: July 08, 2023 For more from Luminous, check out ttbook.org/luminous.

In the last decade, an unlikely place has emerged as a hub for the latest psychedelic renaissance — Madison, Wisconsin. And the Usona Institute is a major part of that. Usona is currently building a 93,000-square foot structure devoted to psychedelics. There’s nothing else like it. The man behind it all is the psychedelic CEO Bill Linton. He prefers to stay out of the spotlight, but he recently sat down for a rare interview with Steve Paulson. In this episode of "Luminous," we go inside Usona’s chemistry lab and go deep with Bill Linton about his pioneering work with psychedelics. Original Air Date: May 17, 2023 Interviews In This Hour: The lab that could supply psilocybin to the world — Psilocybin, the 'God molecule,' and the quest to revolutionize mental health care Guests: Bill Linton, Alex Sherwood Check out the full series at ttbook.org/luminous

In the first episode of "Luminous," our series about the philosophy and the future of psychedelics, how can psilocybin ease our fears about dying? And how can psychedelics change the way we approach the end of life? Original Air Date: April 08, 2023 Interviews In This Hour: How a pioneering psychedelic researcher 'leaned in' to his terminal cancer diagnosis — Dying without fear: How psychedelics can ease the anxiety of terminal illness — The terror and the ecstasy of psychedelics Guests: Roland Griffiths, Lou Lukas, Anthony Bossis Check out the full series at ttbook.org/luminous

Are you ready for the psychedelic revolution? In the next few years, the FDA is likely to approve these mind-bending drugs for treating depression and post-traumatic stress disorder. Some states have already decriminalized psilocybin, the active ingredient in "magic" mushrooms. But for all the headlines, many questions are swirling around this psychedelic renaissance. How do we make these drugs effective, safe and accessible to the people who need the most help? And how can they be used ethically, when much of the knowledge about plant medicines comes from Indigenous cultures?  Psychedelics also raise profound questions about the nature of consciousness and mystical experience. People often describe their psychedelic experiences as “more real” than everyday life. Is this just an illusion, or do these experiences tap into some deeper reality?  In “Luminous,” TTBOOK executive producer Steve Paulson explores the philosophical and cultural implications of psychedelics through conversations with scientists, healers and religious scholars. You can listen to each episode on the radio or find the series plus bonus extended conversations on Apple Podcasts, Spotify, YouTube or wherever you get your podcasts.